Biomarkers for characterization of heart failure – Distinction of heart failure with preserved and reduced ejection fraction

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 272-277

  Sinning, Christoph ^a   Kempf, Tibor ^a   Schwarzl, Michael ^a,c   Lanfermann, Simon ^a   Ojeda, Francisco ^a   Schnabel, Renate B ^a,c   Zengin, Elvin ^a   Wild, Philipp S ^c,d   Lackner, Karl J ^d   Munzel, Thomas ^c,d   Blankenberg, Stefan ^a,c   Wollert, Kai C ^b   Zeller, Tanja ^a,c   Westermann, Dirk ^a,c  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

C reactive protein; Growth differentiation factor 15; Heart failure; Heart failure with reduced and preserved ejection fraction; Soluble source of tumorigenicity 2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; MEMBRANE PROTEIN; SOLUBLE SOURCE OF TUMORIGENICITY 2; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; GDF15 PROTEIN, HUMAN; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART FUNCTION; HUMAN; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RISK FACTOR; BLOOD; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS;

ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STROKE VOLUME;

EID: 85006073662     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.110     Document Type: Article

References (31)

1. [1] Komajda, M., Lam, C.S., Heart failure with preserved ejection fraction: a clinical dilemma. Eur. Heart J. 35:16 (2014 Apr), 1022–1032.
2. [2] Brouwers, F.P., de Boer, R.A., van der Harst, P., Voors, A.A., Gansevoort, R.T., Bakker, S.J., et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur. Heart J. 34:19 (2013 May), 1424–1431.
3. [3] van Veldhuisen, D.J., Linssen, G.C., Jaarsma, T., van Gilst, W.H., Hoes, A.W., Tijssen, J.G., et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J. Am. Coll. Cardiol. 61:14 (2013 Apr 9), 1498–1506.
4. [4] Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 20, 2016 (2016 May).
5. [5] Lin, D.C., Diamandis, E.P., Januzzi, J.L. Jr., Maisel, A., Jaffe, A.S., Clerico, A., Natriuretic Peptides in Heart Failure. Clin. Chem. 60:8 (2014), 1040–1046.
6. [6] Chan, M.M., Santhanakrishnan, R., Chong, J.P., Chen, Z., Tai, B.C., Liew, O.W., et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur. J. Heart Fail. 18:1 (2016 Jan), 81–88.
7. [7] Kempf, T., Zarbock, A., Widera, C., Butz, S., Stadtmann, A., Rossaint, J., et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat. Med. 17:5 (2011 May), 581–588.
8. [8] Chen, L.Q., de Lemos, J.A., Das, S.R., Ayers, C.R., Rohatgi, A., Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin. Chem. 59:3 (2013 Mar), 536–546.
9. [9] Li, X., Chen, C., Gan, F., Wang, Y., Ding, L., Hua, W., Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovasc. Disord., 14, 2014, 67.
10. [10] Wild, P.S., Zeller, T., Beutel, M., Blettner, M., Dugi, K.A., Lackner, K.J., et al. The Gutenberg Health Study. Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz 55:6–7 (2012 Jun), 824–829.
11. [11] Lean, M.E., Han, T.S., Morrison, C.E., Waist circumference as a measure for indicating need for weight management. BMJ 311:6998 (1995 Jul 15), 158–161.
12. [12] Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F. 3rd, Feldman, H.I., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150:9 (2009 May 5), 604–612.
13. [13] Wild, P.S., Sinning, C.R., Roth, A., Wilde, S., Schnabel, R.B., Lubos, E., et al. Distribution and categorization of left ventricular measurements in the general population: results from the population-based Gutenberg heart study. Circ. Cardiovasc. Imaging 3:5 (2010 Sep), 604–613.
14. [14] Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., et al. Recommendations for chamber quantification. Eur. J. Echocardiogr. 7:2 (2006 Mar), 79–108.
15. [15] Schwarzl, M., Ojeda, F., Zeller, T., Seiffert, M., Becher, P.M., Munzel, T., et al. Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort. Eur. Heart J., 7, 2016 Apr, 10.1093/eurheartj/ehw120.
16. [16] Santhanakrishnan, R., Chong, J.P., Ng, T.P., Ling, L.H., Sim, D., Leong, K.T., et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur. J. Heart Fail. 14:12 (2012 Dec), 1338–1347.
17. [17] Kempf, T., Horn-Wichmann, R., Brabant, G., Peter, T., Allhoff, T., Klein, G., et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin. Chem. 53:2 (2007 Feb), 284–291.
18. [18] Wang, T.J., Larson, M.G., Levy, D., Benjamin, E.J., Leip, E.P., Wilson, P.W., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109:5 (2004 Feb 10), 594–600.
19. [19] de Jager, S.C., Bermudez, B., Bot, I., Koenen, R.R., Bot, M., Kavelaars, A., et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J. Exp. Med. 208:2 (2011 Feb 14), 217–225.
20. [20] Wollert, K.C., Kempf, T., Growth differentiation factor 15 in heart failure: an update. Curr. Heart Fail. Rep. 9:4 (2012 Dec), 337–345.
21. [21] Anand, I.S., Kempf, T., Rector, T.S., Tapken, H., Allhoff, T., Jantzen, F., et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122:14 (2010 Oct 5), 1387–1395.
22. [22] Wollert, K.C., Kempf, T., GDF-15 in heart failure: providing insight into end-organ dysfunction and its recovery?. Eur. J. Heart Fail. 14:11 (2012 Nov), 1191–1193.
23. [23] Chan, M.M., Santhanakrishnan, R., Chong, J.P., Chen, Z., Tai, B.C., Liew, O.W., et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur. J. Heart Fail. 18:1 (2016 Jan), 81–88.
24. [24] Liew, F.Y., Pitman, N.I., McInnes, I.B., Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10:2 (2010 Feb), 103–110.
25. [25] Kalogeropoulos, A., Georgiopoulou, V., Psaty, B.M., Rodondi, N., Smith, A.L., Harrison, D.G., et al. Inflammatory markers and incident heart failure risk in older adults: the health ABC (health, aging, and body composition) study. J. Am. Coll. Cardiol. 55:19 (2010 May 11), 2129–2137.
26. [26] Ahmed, A., 1-year mortality after first hospitalization for heart failure was similar in patients with preserved or reduced ejection fraction. ACP J. Club, 145(3), 2006 Nov–Dec, 78.
27. [27] Tribouilloy, C., Rusinaru, D., Mahjoub, H., Souliere, V., Levy, F., Peltier, M., et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur. Heart J. 29:3 (2008 Feb), 339–347.
28. [28] Westermann, D., Kasner, M., Steendijk, P., Spillmann, F., Riad, A., Weitmann, K., et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 117:16 (2008 Apr 22), 2051–2060.
29. [29] Borlaug, B.A., Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Circ. J. 78:1 (2014), 20–32.
30. [30] Cheng, J.M., Akkerhuis, K.M., Battes, L.C., van Vark, L.C., Hillege, H.L., Paulus, W.J., et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur. J. Heart Fail. 15:12 (2013 Dec), 1350–1362.
31. [31] Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62:4 (2013 Jul 23), 263–271.